Angioimmunoblastic T-cell Lymphoma Clinical Trials

111 clinical trials for Angioimmunoblastic T-cell Lymphoma across international registries, including 4 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL) — RECRUITING · PHASE1
• A Registry for People With T-cell Lymphoma — RECRUITING
• Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma — RECRUITING · PHASE3
• Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma — RECRUITING · PHASE1
• Phase ll Trial of Fludarabine & Cyclophosphamide followed by Thalidomide for Angioimmunoblastic Lymphoma — COMPLETED · PHASE2
• Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma — SUSPENDED · PHASE2
• Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies — SUSPENDED · PHASE1
• Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma — SUSPENDED · PHASE1
• Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency — ACTIVE_NOT_RECRUITING · NA
• Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma — COMPLETED · PHASE2
• Tazemetostat Plus CHOP in 1L T-cell Lymphoma — WITHDRAWN · PHASE2
• Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymphoma — TERMINATED · PHASE1
• Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant — ACTIVE_NOT_RECRUITING
• Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas — ACTIVE_NOT_RECRUITING · PHASE1
• A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) — COMPLETED · PHASE2
• Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma — ACTIVE_NOT_RECRUITING · PHASE2
• Clinical Study of CEP+Dasatinib + Azacytidine in First-line Treatment of. Angioimmunoblastoma Foresight — ACTIVE_NOT_RECRUITING · PHASE4
• Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies — COMPLETED · PHASE1
• Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms — COMPLETED · PHASE2
• CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma — COMPLETED · PHASE1
• Clinical Study of Mitoxantrone Liposome and Azacitidine in the Treatment of R/R AITL — OTHER · PHASE1
• Ipilimumab and Local Radiation for Selected Solid Tumors — TERMINATED · PHASE1
• Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies — SUSPENDED · PHASE1
• Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma — COMPLETED · PHASE2
• Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma — COMPLETED · PHASE1
• A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological Types — OTHER
• Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma. — OTHER · NA
• Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma — COMPLETED · PHASE1
• Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma — COMPLETED · PHASE2
• Study Evaluating the Safety and Efficacy of C-CHOP in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma — OTHER · PHASE2
• An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma — OTHER · PHASE1
• Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell Lymphoma — OTHER · PHASE2
• Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas — TERMINATED · PHASE1
• Sintilimab in Combination With Chidamide in Refractory and Relapsed AITL — OTHER · PHASE2
• Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies — TERMINATED · PHASE1
• Rituximab Combined With Chidamide and Lenalidomide for r/r AITL — OTHER · NA
• Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation — COMPLETED · PHASE1
• CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study — OTHER · PHASE1
• Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma — COMPLETED · PHASE2
• Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma — COMPLETED · PHASE1
• CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL — OTHER · PHASE2
• Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma — COMPLETED · PHASE1
• Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer — COMPLETED · PHASE2
• Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies — COMPLETED · PHASE2
• Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies — COMPLETED · NA
• Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer — COMPLETED · PHASE1
• Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant — COMPLETED · PHASE1
• Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma — COMPLETED · NA
• Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors — COMPLETED · PHASE1
• Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma — COMPLETED · NA

Refine this search